Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00909818 |
Recruitment Status : Unknown
Verified August 2021 by Birgitte Offersen, Danish Breast Cancer Cooperative Group.
Recruitment status was: Active, not recruiting
First Posted : May 29, 2009
Last Update Posted : August 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer Carcinoma in Situ of the Breast | Radiation: standard fractionated radiotherapy Radiation: hypofractionated radiotherapy | Not Applicable |
The randomization is between 50 Gy/25 fractions, 2.0 Gy per fraction, 5 fractions weekly, and 40 Gy/15 fractions, 2.67 Gy per fraction, 5 fractions weekly. The primary endpoint is late radiation morbidity; secondly, we want to investigate the frequency of local recurrences, and try to establish a genetic risk profile for development of late radiation morbidity.
The hypothesis is that women operated with breast conserving strategy for early breast cancer can be offered moderately hypofractionated radiotherapy without developing more late radiation morbidity compared to standard fractionated radiotherapy.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 976 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase III Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology) |
Actual Study Start Date : | May 14, 2009 |
Estimated Primary Completion Date : | May 2024 |
Estimated Study Completion Date : | May 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: standard fractionated radiotherapy
50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
|
Radiation: standard fractionated radiotherapy
standard fractionated radiotherapy 50 Gy/25 fractions |
Experimental: hypofractionated radiotherapy
hypofractionated radiotherapy 40 Gy/15 fractions
|
Radiation: hypofractionated radiotherapy
hypofractionated radiotherapy 40 Gy/15 fractions |
- Grade 2 or 3 fibrosis 3 years after radiotherapy [ Time Frame: 3 years ]
- Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival [ Time Frame: 10 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 41 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
operated with breast conserving strategy for:
- invasive breast cancer, pT1-2, pN0-1mi, M0 OR
- carcinoma in situ of the breast
Exclusion Criteria:
- previous radiation of the breast/thorax
- breast implants
- pregnant/lactating
- comorbidity which may hinder the patient in completing the therapy and complete follow up for 10 years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00909818
Denmark | |
The Danish Breast Cancer Cooperative Group | |
Copenhagen, Denmark, DK-2100 Ø |
Study Chair: | Lars Stenbygaard, MD | Aalborg University Hospital | |
Study Chair: | Birgitte Offersen, MD, Ph.D | Aarhus University Hospital | |
Study Chair: | Erik Jakobsen, MD | Vejle Hospital | |
Study Chair: | Mette H Nielsen, MD, phd | Odense University Hospital | |
Principal Investigator: | Birgitte Offersen, MD, phd | Aarhus University Hospital | |
Study Chair: | Mechthild Krause, M.D., Prof | University Clinic Carl Gustav Carus Dresden | |
Study Chair: | Andreas Schreiber, M.D., Ph.D. | Praxis für Strahlentherapie am Klinikum Dresden-Friedrichstadt | |
Study Chair: | Ingvil Mjaaland, M.D. | Helse Stavanger HF, Sorlandet Sykehus HF | |
Study Chair: | Unn-Miriam Kasti, M.D. | Kristiansand Sykehus |
Responsible Party: | Birgitte Offersen, M.D., ph.d., associate professor, Danish Breast Cancer Cooperative Group |
ClinicalTrials.gov Identifier: | NCT00909818 |
Other Study ID Numbers: |
DBCG hypo protocol CIRRO IP030209 The Danish Cancer Society |
First Posted: | May 29, 2009 Key Record Dates |
Last Update Posted: | August 24, 2021 |
Last Verified: | August 2021 |
Breast Neoplasms Carcinoma in Situ Breast Carcinoma In Situ Neoplasms by Site Neoplasms |
Breast Diseases Skin Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |